Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Gyre Therapeutics's Sloan Ratio for the quarter that ended in Jun. 2026 was -7.72%.
As of Jun. 2026, Gyre Therapeutics has a Sloan Ratio of -7.72%, indicating the company is in the safe zone and there is no funny business with accruals.
Gyre Therapeutics (NAS:GYRE) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2026, Gyre Therapeutics has a Sloan Ratio of -7.72%, indicating the company is in the safe zone and there is no funny business with accruals.
Gyre Therapeutics Sloan Ratio % Related Terms
Gyre Therapeutics Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Gyre Therapeutics's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gyre Therapeutics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics Sloan Ratio % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Gyre Therapeutics's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Gyre Therapeutics's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was 3.61 (Sep. 2025 ) + -1.723 (Dec. 2025 ) + -8.691 (Mar. 2026 ) + -10.605 (Jun. 2026 ) = $-17.4 Mil.
Gyre Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was 14.238 (Sep. 2025 ) + -5.625 (Dec. 2025 ) + 3.18 (Mar. 2026 ) + -16.728 (Jun. 2026 ) = $-4.9 Mil.
Gyre Therapeutics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 was -5.643 (Sep. 2025 ) + 1.848 (Dec. 2025 ) + -3.055 (Mar. 2026 ) + 9.757 (Jun. 2026 ) = $2.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics (GYRE) has a Sloan Ratio % of -7.72% as of Jun. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Gyre Therapeutics and its competitors.
Is Gyre Therapeutics' Sloan Ratio % too high?
Gyre Therapeutics' current Sloan Ratio % is -7.72%. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Sloan Ratio % compare to OCS and RIGL?
Gyre Therapeutics' Sloan Ratio % of -7.72% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Biotechnology company?
A good Sloan Ratio % depends on the Biotechnology industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Gyre Therapeutics and its competitors. Gyre Therapeutics's current Sloan Ratio % is -7.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.71, compared to a current price of $6.72 — trading 30.8% below its estimated fair value. The current Sloan Ratio % is -7.72%. Gyre Therapeutics' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current Sloan Ratio % is -7.72% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (GYRE) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of $6.72 is trading 30.8% below its estimated GF Value™ of $9.71.
GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.
Key valuation signals for GYRE:
Sloan Ratio %: -7.72%
GF Value™: $9.71 vs. price of $6.72 (30.8% below fair value)
No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score
Get the complete analysis for GYRE
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GYRE has been successfully added to your 
